Contact this trialFirst, we need to learn more about you.
Topoisomerase I inhibitor
Liposomal Irinotecan +1 More for Brain Tumor
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial is testing a new combo cancer treatment of Nal-IRI and pembrolizumab. Nal-IRI is given IV every 2 weeks, starting at 50mg/m2, and pembrolizumab is given IV every 6 weeks at 400mg. Treatment will continue until the cancer progresses, the patient has intolerable side effects, or the patient/doctor decides to discontinue treatment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service